-
NRx Pharmaceuticals Achieves Debt-Free Status Ahead of Drug Approvals
Summary of the Article/Press Release On December 18, 2025, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders like suicidal depression and PTSD, announced that it has fully eliminated its balance sheet debt. CEO Dr. Jonathan Javitt thanked Anson Funds for their support during tough biotech market…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF SEPTEMBER 28, 2025 – OCTOBER 04, 2025
September 28, 2025 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Clinical Trial 09/30/2025 AGEN 53.89 6,179 0.00 Clinical Trial 09/30/2025 BTAI 53.32 4,080 0.00 PDUFA 09/30/2025 FBIO 28.17 1,996 0.00 Clinical Trial 09/30/2025 ALEC 25.87 730 0.00 Clinical Trial 09/30/2025 STRO 44.79 170 0.00 Clinical Trial 09/30/2025 RCKT 34.65 2,506…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF FEBRUARY 2, 2025 – FEBRUARY 08, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Data Release 02/03/2025 IVVD 55.1 44 0.36 Conference 02/05/2025 ANAB 30.6 2,770 17.93 Conference 02/05/2025 CABA 22.5 12,509 2.39 Conference 02/05/2025 ABSI 23.2 14,305 3.71 Conference 02/06/2025 PRAX 33.6 13,932 76.55 Conference 02/06/2025 FBRX 23.4 504 15.89 Conference 02/06/2025 ADCT 32.3 172 1.68…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF JANUARY 26, 2025 – FEBRUARY 01, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Conference 01/28/2025 LXRX 49.9 4,606 0.99 Conference 01/28/2025 IPA 28.7 3,588 0.58 Webinar 01/29/2025 OTLK 21.0 1,839 1.99 Corporate Event 01/29/2025 ZNTL 58.3 4,312 2.22 FDA Event 01/30/2025 VRTX 17.34 48,375 439.62 FDA Event 01/31/2025 AXSM 13.99 45,376 103.11 Clinical Trial 02/01/2025 SUPN…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 29, 2024 – JANUARY 04, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ FDA Event 12/29/2024 NBIX 4.2 1,817 139.44 FDA Event 12/29/2024 BMY 2.5 5,932 57.68 Clinical Trial 12/30/2024 BCLI 42.3 782 2.45 FDA Event 12/30/2024 NBIX 4.2 1,817 139.44 Clinical Trial 12/31/2024 ALDX 13.0 6,889 4.94 Clinical Trial 12/31/2024 ABBV 2.1 6,221 178.01 Clinical…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 10-16, 2023
December 10, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/10/2023 AUTL 21.1 4,281 $4.36 Conference 12/10/2023 BLUE 26.9 18,165 $2.86 Conference 12/10/2023 BMEA 43.0 49,731 $16.89 Announcement 12/11/2023 COGT 28.9 11,224 $8.64 Conference 12/11/2023 BLUE 26.9 18,165 $2.86 Conference 12/11/2023 HARP 35.3 295 $8.94 Conference 12/14/2023 BCYC 24.0 2,878…
-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…